Received Sep 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | 1 | 944608 | IM / LA |
Patient Had First Dose of Heplisav-B in June of 2024, Hasn't Received The Second Dose; Initial report received on 02-Sep-2025. A pharmacist reported that a 40-year-old female received the first dose of HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization in Jun-2024 and has not received the second dose. Medical history included allergies to penicillin, imidazole, and COX-2 inhibitors No concomitant medications were reported. In Jun-2024, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot number 944608, expiration date 27-Apr-2026; NDC number not available)] intramuscularly in the left deltoid. At the time of this report, the patient had not received the second dose of HEPLISAV-B. The patient had no other side effects reported. No other information was available. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.
Medical History/Concurrent Conditions: Drug allergy (Imidizole); Drug allergy (Cox-2 Inhibitors); Penicillin allergy